Flow-cytometry Assessment of DNA content and Immunophenotyping of Immune-cells in Lymph-node-specimens as a Potential Diagnostic Signature of Aggressiveness in B-Non-Hodgkin Lymphomas.

Cell Cells, tumor Cycle Indexing, immune Lymph Lymphoma, DNA Lymphoma, Indolent Microenvironment Node (LN), Aggrressive

Journal

Annals of hematology
ISSN: 1432-0584
Titre abrégé: Ann Hematol
Pays: Germany
ID NLM: 9107334

Informations de publication

Date de publication:
23 May 2024
Historique:
received: 15 02 2024
accepted: 14 05 2024
medline: 23 5 2024
pubmed: 23 5 2024
entrez: 22 5 2024
Statut: aheadofprint

Résumé

Flow-cytometry (FC) is a powerful tool that can assist in lymphoma diagnosis in lymph node (LN) specimens. Although lymphoma diagnosis and classification are mainly based on tumor cell characteristics, surrounding cells are less employed in this process. We retrospectively investigated alterations in the ploidy status, proliferative cell fraction (PF) and the percentages of surrounding immune cells in 62 consecutive LN specimens with B-Cell Non-Hodgkin Lymphoma (B-NHL) that were submitted for FC evaluation between 2019-2022. Compared with indolent B-NHLs, aggressive B-NHLs show increased DNA aneuploidy and PF, increased monocytes, immature-granulocytes, mature granulocytes, CD8

Identifiants

DOI: 10.1007/s00277-024-05807-8 PMID: 38777843
pubmed: 38777843
doi: 10.1007/s00277-024-05807-8
pii: 10.1007/s00277-024-05807-8
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2024. The Author(s).

Références

Brown M, Wittwer C (2000) ‘Flow cytometry: Principles and clinical applications in hematology. Clinical Chemistry 46(8 II):1221–1229. https://doi.org/10.1093/clinchem/46.8.1221
doi: 10.1093/clinchem/46.8.1221 pubmed: 10926916
Martig DS, Fromm JR (2022) A comparison and review of the flow cytometric findings in classic Hodgkin lymphoma, nodular lymphocyte predominant Hodgkin lymphoma, T cell/histiocyte rich large B cell lymphoma, and primary mediastinal large B cell lymphoma. Cytometry B Clin Cytom 102(1):14–25. https://doi.org/10.1002/cyto.b.22045
doi: 10.1002/cyto.b.22045 pubmed: 34878224
McKinnon KM (2018) Flow Cytometry: An Overview. Current protocols in immunology 120: 5.1.1–5.1.11. https://doi.org/10.1002/cpim.40
Gunduz E et al (2013) ‘The role of flow cytometry in the diagnosis of non-Hodgkin’s lymphoma, Hodgkin’s lymphoma, granulomatous inflammation and reactive lymph node specimens. Journal of B. U. ON 18(3):739–745
pubmed: 24065493
Rimsza LM, Jaramillo MC (2014) ‘Indolent lymphoma: Follicular lymphoma and the microenvironment-insights from gene expression profiling.’ Hematology 2014(1):163–168. https://doi.org/10.1182/asheducation-2014.1.163
doi: 10.1182/asheducation-2014.1.163 pubmed: 25696850
Azoulay D et al (2020) Flow cytometry aneuploidy and cell cycle indexing as a possible tool for differentiating between CD10+ diffuse large B-cell lymphoma and follicular lymphoma. Cytometry Part B - Clinical Cytometry 98(5):449–453. https://doi.org/10.1002/cyto.b.21861
doi: 10.1002/cyto.b.21861 pubmed: 31816181
Braylan RC et al (1984) Cellular DNA of human neoplastic B-cells measured by flow cytometry. Cancer Res 44(11), pp. 5010–6. Available at: http://www.ncbi.nlm.nih.gov/pubmed/6435862 (Accessed: 27 December 2023)
Srigley J et al (1985) Heterogeneity of Non-Hodgkin’s Lymphoma Probed by Nucleic Acid Cytometry. Available at: http://ashpublications.org/blood/article-pdf/65/5/1090/1639296/1090.pdf
Lehtinen T (1989) Flow cytometric dna analysis of 199 histologically favourable or unfavourable non-hodgkin lymphomas. J Pathol
Pinto AE et al (2003) Flow cytometric S-phase fraction as a complementary biological parameter for the cytological grading of non-Hodgkin’s lymphoma. Diagn Cytopathol 29(4):194–199. https://doi.org/10.1002/dc.10298
doi: 10.1002/dc.10298 pubmed: 14506670
Tarte K (2017) Role of the microenvironment across histological subtypes of NHL. Hematology 1:610–617. https://doi.org/10.1182/asheducation-2017.1.610
doi: 10.1182/asheducation-2017.1.610
Wilkinson ST et al (2012) Lymphoid neoplasia Partial plasma cell differentiation as a mechanism of lost major histocompatibility complex class II expression in diffuse large B-cell lymphoma. https://doi.org/10.1182/blood-2011-07  
Scott DW, Gascoyne RD (2014) The tumour microenvironment in B cell lymphomas. Nature Reviews Cancer. Nature Publishing Group 517–534. https://doi.org/10.1038/nrc3774  
Yang ZZ et al (2006) Attenuation of CD8+ T-cell function by CD4+CD25 + regulatory T cells in B-cell non-Hodgkin’s lymphoma. Can Res 66(20):10145–10152. https://doi.org/10.1158/0008-5472.CAN-06-1822
doi: 10.1158/0008-5472.CAN-06-1822
Menter T, Tzankov A (2019) ‘Lymphomas and Their Microenvironment: A Multifaceted Relationship. Pathobiology : J Immunopathol Mol Cell Biol 86(5–6):225–236. https://doi.org/10.1159/000502912
doi: 10.1159/000502912
Tzankov A et al (2007) Angiogenesis in nodal B cell lymphomas: A high throughput study. J Clin Pathol 60(5):476–482. https://doi.org/10.1136/jcp.2006.038661
doi: 10.1136/jcp.2006.038661 pubmed: 16790692
Kumar D, Xu ML (2018) ‘Microenvironment Cell Contribution to Lymphoma Immunity, Frontiers in Oncology. Frontiers Media SA. https://doi.org/10.3389/fonc.2018.00288
doi: 10.3389/fonc.2018.00288
Tian X et al (2019) Tumor-derived exosomes, myeloid-derived suppressor cells, and tumor microenvironment. Journal of Hematology and Oncology. BioMed Central Ltd. https://doi.org/10.1186/s13045-019-0772-z  
Augier S et al (2010) Inflammatory blood monocytes contribute to tumor development and represent a privileged target to improve host immunosurveillance. J Immunol 185(12):7165–7173. https://doi.org/10.4049/jimmunol.0902583
doi: 10.4049/jimmunol.0902583 pubmed: 21078911
Yao J et al (2019) Human double negative T cells target lung cancer via ligand-dependent mechanisms that can be enhanced by IL-15. J Immuno Therapy Cancer 7(1). https://doi.org/10.1186/s40425-019-0507-2
Sansregret L, Swanton C (2017) The role of aneuploidy in cancer evolution, Cold Spring Harbor Perspectives in Medicine. Cold Spring Harbor Laboratory Press. https://doi.org/10.1101/cshperspect.a028373  

Auteurs

David Azoulay (D)

Azrieli Faculty of Medicine, Bar Ilan University, Safed, Israel. davida@gmc.gov.il.
Hematology Unit and Laboratories, Galilee Medical Center, Nahariya, Israel. davida@gmc.gov.il.
ORCID: 0000-0002-3451-5737

Tal Tapuchi (T)

Azrieli Faculty of Medicine, Bar Ilan University, Safed, Israel.

Ohad Ronen (O)

Azrieli Faculty of Medicine, Bar Ilan University, Safed, Israel.
Department of Otolaryngology - Head and Neck Surgery, Director Head and Neck Surgery Unit, Galilee Medical Center, Nahariya, Israel.

Luiza Akria (L)

Azrieli Faculty of Medicine, Bar Ilan University, Safed, Israel.
Hematology Unit and Laboratories, Galilee Medical Center, Nahariya, Israel.

Hector I Cohen (HI)

Azrieli Faculty of Medicine, Bar Ilan University, Safed, Israel.
Pathology Unit and Laboratories, Galilee Medical Center, Nahariya, Israel.

Celia Surio (C)

Azrieli Faculty of Medicine, Bar Ilan University, Safed, Israel.
Hematology Unit and Laboratories, Galilee Medical Center, Nahariya, Israel.

Svetlana Rodin Chepa (SR)

Hematology Unit and Laboratories, Galilee Medical Center, Nahariya, Israel.

Elizabeth Eshel (E)

Hematology Unit and Laboratories, Ziv Medical Center, Safed, Israel.

Moran Zarfati (M)

Azrieli Faculty of Medicine, Bar Ilan University, Safed, Israel.
Hematology Unit and Laboratories, Galilee Medical Center, Nahariya, Israel.

Galia Stemer (G)

Azrieli Faculty of Medicine, Bar Ilan University, Safed, Israel.
Hematology Unit and Laboratories, Galilee Medical Center, Nahariya, Israel.

Netanel A Horowitz (NA)

The Ruth and Bruce Rappaport Faculty of Medicine, Department of Hematology and BMT, Rambam Health Care Campus, Israel Institute of Technology, Haifa, TechnionHaifa, Israel.

Classifications MeSH